开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09939 开拓药业-B

未开盘 01-13 16:08:12

2.340

+0.090

+4.00%

最高2.390	最低2.280	成交量339.80万
今开2.300	昨收2.250	日振幅4.89%
总市值11.68亿	流通市值11.68亿	总股本4.99亿
成交额791.80万	换手率0.68%	流通股本4.99亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09939","market":"HK","secType":"STK","nameCN":"开拓药业-B","latestPrice":2.34,"timestamp":1768291692011,"preClose":2.25,"halted":0,"volume":3398000,"delay":0,"floatShares":499000000,"shares":499000000,"eps":-0.360537,"marketStatus":"未开盘","change":0.09,"latestTime":"01-13 16:08:12","open":2.3,"high":2.39,"low":2.28,"amount":7917985,"amplitude":0.048889,"askPrice":2.34,"askSize":129500,"bidPrice":2.29,"bidSize":6500,"shortable":0,"etf":0,"ttmEps":-0.367,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768354200000},"marketStatusCode":0,"adr":0,"listingDate":1590076800000,"exchange":"SEHK","adjPreClose":2.25,"openAndCloseTimeList":[[1768267800000,1768276800000],[1768280400000,1768291200000]],"volumeRatio":1.470995670995671,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09939","defaultTab":"news","newsList":[{"id":"2603490635","title":"【新股IPO】上海生生医药冷链科技股份有限公司向港交所主板提交上市申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2603490635","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603490635?lang=zh_cn&edition=full","pubTime":"2026-01-13 23:44","pubTimestamp":1768319081,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据港交所1月13日披露，上海生生医药冷链科技股份有限公司向港交所主板提交上市申请，中金公司、国金证券 为其联席保荐人。公司是中国领先的制药及生命科学行业一体化温控供应链服务提供商，核心聚焦于临床试验温控供应链服务，同时延伸至商业化阶段的医疗产品温控供应链服务，以及温控装备与材料的研发制造，打造全生命周期、全应用场景的温控供应链综合能力。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/MWMzMWU4NjgxMDkxMjQ0ODA=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MWMzMWU4NjgxMDkxMjQ0ODA=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1973159","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","BK1515","BK1574","HEXmain","BK1161","159938"],"gpt_icon":0},{"id":"2603354638","title":"百奥泰（688177）披露收到吉瑞医药里程碑付款进展公告，1月13日股价上涨1.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603354638","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603354638?lang=zh_cn&edition=full","pubTime":"2026-01-13 22:29","pubTimestamp":1768314551,"startTime":"0","endTime":"0","summary":"截至2026年1月13日收盘，百奥泰报收于25.76元，较前一交易日上涨1.26%，最新总市值为106.67亿元。该股当日开盘25.44元，最高26.33元，最低25.44元，成交额达1.09亿元，换手率为1.01%。公司近日收到吉瑞医药支付的250万美元里程碑款，实际到账金额扣除银行手续费。BAT2206已在美欧获批上市，商品名为STARJEMZA和Usymro，中国上市申请正在评审中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300042428.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688177","BK1574","BK1515","09939","BK1161","BK0239","159938"],"gpt_icon":0},{"id":"2603156684","title":"1月13日欧康医药发布公告，股东减持36.19万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2603156684","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603156684?lang=zh_cn&edition=full","pubTime":"2026-01-13 21:01","pubTimestamp":1768309263,"startTime":"0","endTime":"0","summary":"证券之星消息，1月13日欧康医药发布公告《欧康医药:员工持股平台减持股份结果公告》，其股东成都欧康企业管理中心(有限合伙)于2026年1月10日至2026年1月12日间合计减持36.19万股，占公司目前总股本的0.3593%，变动期间该股股价上涨2.33%，截止1月12日收盘报13.2元。股东增减持详情见下表：根据欧康医药2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300040202.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","BK1574","159938","BK1515","BK1161"],"gpt_icon":0},{"id":"2603668334","title":"最牛飙升超65%！医药+AI 猛拉","url":"https://stock-news.laohu8.com/highlight/detail?id=2603668334","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603668334?lang=zh_cn&edition=full","pubTime":"2026-01-13 19:03","pubTimestamp":1768302196,"startTime":"0","endTime":"0","summary":"【导读】医药+AI大放异彩：方舟健客狂飙超76%！药明康德、药明生物领涨蓝筹1月13日，港股震荡上涨，医药股领涨，医药+AI大放异彩！恒生指数收涨0.9%，报26848.47点；恒生科技指数微涨0.11%，报5869.79点；恒生中国企业指数上涨0.71%，报9285.41点。当日市场成交额为3151.92亿港元，较前一交易日3062.23亿港元有所增加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601133617574616.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601133617574616.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09939","159938","BK1515","BK1574","BK1161"],"gpt_icon":0},{"id":"2603593503","title":"中赋科技：子公司鼎赋医药尚处于前期筹备阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2603593503","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603593503?lang=zh_cn&edition=full","pubTime":"2026-01-13 15:06","pubTimestamp":1768287981,"startTime":"0","endTime":"0","summary":"证券之星消息，中赋科技(300692)01月13日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘您好，请问子公司鼎赋医药科技目前业务涉及软件开发，人工智能和化妆品相关的业务，目前业务开展情况如何，接下来的业务发展规划如何，请详细说说中赋科技回复：尊敬的投资者您好，子公司鼎赋医药营业范围的注册登记是基于相关法律法规，根据公司战略发展规划的前瞻性布局所履行的一般性工商手续。目前鼎赋医药尚处于前期筹备阶段，具体请以公司披露的定期报告及临时公告为准。感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300019583.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","BK1574","09939","BK1161","159938"],"gpt_icon":0},{"id":"2603857150","title":"勤浩医药完成超3亿元Crossover轮融资 持续创新再提速","url":"https://stock-news.laohu8.com/highlight/detail?id=2603857150","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603857150?lang=zh_cn&edition=full","pubTime":"2026-01-13 11:41","pubTimestamp":1768275673,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，1月13日，致力于利用组合技术平台开发全球新一代抗肿瘤小分子药物的研发企业勤浩医药宣布，已完成超3亿元人民币Crossover轮融资。未来，勤浩医药将依托AI赋能的高效创新体系，聚焦未被满足的临床需求，携手产学研各界，继续推动具有全球竞争力的创新药开发，为患者带来突破性治疗方案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392077.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","159938","09939","BK1161","BK1574"],"gpt_icon":0},{"id":"2603950262","title":"A股、港股医药股今日大涨，这些利好因素在刺激","url":"https://stock-news.laohu8.com/highlight/detail?id=2603950262","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603950262?lang=zh_cn&edition=full","pubTime":"2026-01-13 11:37","pubTimestamp":1768275475,"startTime":"0","endTime":"0","summary":"1月13日上午，A股以及港股的医药股集体出现走强趋势。当前，已有重磅对外授权交易揭晓。这笔交易刺激了A股、港股市场中的一些双抗概念股股价大涨，1月13日上午，宜明昂科港股股价盘中涨幅一度超过10.10%；三生国健A股股价涨幅也超过4%。同样，A股以及港股的医药外包股齐齐出现股价大涨局面，如药明康德A股跟港股上午盘中股价涨幅超过6%；药明生物股价涨幅也超过5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113113932a4bcec89&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260113113932a4bcec89&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0307460666.USD","LU1720050803.USD","LU1969619763.USD","LU0823426308.USD","LU0051755006.USD","LU0979878070.USD","LU0456827905.SGD","SG9999002562.SGD","02616","LU0181495838.USD","02269","LU0039217434.USD","LU0043850808.USD","BK1515","LU0516422366.SGD","LU0516422440.USD","LU0856984785.SGD","LU0320764599.SGD","LU3063872942.SGD","LU0516423174.USD","BK1576","LU0417516902.SGD","01541","LU0516422952.EUR","BK1610","LU0359201612.USD","LU2039709279.SGD","LU1688375341.USD","LU2328871848.SGD","LU0348825331.USD","LU0052750758.USD","LU1242518931.SGD","02179","LU0819121731.USD","09995","LU0327786744.USD","LU0417516738.SGD","LU0516423091.SGD","09939","LU1880383366.USD","LU1794554557.SGD","BK1161","IE00B0JY6N72.USD","LU0823426480.USD","LU0588546209.SGD","BK1574","LU0359202008.SGD","LU1242518857.USD","02126","LU0708995583.HKD"],"gpt_icon":0},{"id":"2603575804","title":"恒生医疗保健指数急升逾3.3% 医药股普遍拉升 讯飞医疗科技(02506)涨12.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603575804","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603575804?lang=zh_cn&edition=full","pubTime":"2026-01-13 10:03","pubTimestamp":1768269829,"startTime":"0","endTime":"0","summary":"金吾财讯 | 恒生医疗保健指数急升逾3.3%，医药股普遍拉升，讯飞医疗科技 涨12.87%，医脉通涨12.56%，英硅智能涨12.34%，医渡科技涨11.34%，方舟健客涨10.43%，阿里健康涨9.71%，微创机器人-B涨5.62%，京东健康涨5.32%，晶泰控股涨3.11%，平安好医生涨2.04%，固生堂涨0.20%。2026年年初以来，恒生医疗保健指数涨幅为12.4%，跑赢恒生指数10.0个百分点。同时，受到AI主题热度高涨影响，AI医疗概念走强，高增速、业绩兑现度高的主题标的医脉通、平安好医生涨幅明显。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1973101","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1591","BK1574","LU0456827905.SGD","BK1501","06086","BK1583","06618","BK1502","02228","02192","BK1589","01833","BK1247","BK1610","BK1617","00241","BK1615","BK1515","159506","02252","LU0051755006.USD","BK1584","BK1142","BK1161","BK1141","BK1100","BK1587","09939","SGXZ62798434.SGD","LU1046422090.SGD","LU0049112450.USD","02506","BK1189","BK1219","02158","159938","03696","BK1518","BK1571","86618","02273","LU1235295612.USD","SGXZ86797644.SGD"],"gpt_icon":0},{"id":"2603578470","title":"重磅进展！和誉医药(02256)腱鞘巨细胞瘤新药贝捷迈®上市申请获FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2603578470","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603578470?lang=zh_cn&edition=full","pubTime":"2026-01-13 09:21","pubTimestamp":1768267282,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2026年1月13日，和誉医药今日宣布，其自主研发的新型、口服、高选择性且高效的小分子集落刺激因子1受体抑制剂贝捷迈用于腱鞘巨细胞瘤患者系统性治疗的新药申请已获美国食品药品监督管理局正式受理。此次贝捷迈NDA获FDA受理，主要基于全球多中心、随机、双盲、安慰剂对照III期MANEUVER研究的积极结果。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1392004.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2476274308.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","09939","LU2778985437.USD","LU2476274720.SGD","IE00BPRC5H50.USD","BK1574","02256","LU2488822045.USD","159938","BK1515","BK1161"],"gpt_icon":0},{"id":"2603522070","title":"一批港股公司预告2025年业绩 黄金医药等板块报喜","url":"https://stock-news.laohu8.com/highlight/detail?id=2603522070","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603522070?lang=zh_cn&edition=full","pubTime":"2026-01-13 07:22","pubTimestamp":1768260167,"startTime":"0","endTime":"0","summary":"每经AI快讯，Wind数据显示，截至1月12日，已有近20家港股上市公司预告截至2025年12月31日的年度业绩情况。其中，11家公司业绩预增，2家公司预计减亏，1家公司预计扭亏。分行业来看，业绩预增的公司中“金矿股”占了大半，灵宝黄金、紫金黄金国际等公司更是实现净利润倍增；港股热门的生物医药、消费赛道，亦有公司预计将交出亮丽成绩单。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601133616381155.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601133616381155.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159831","09939","159938","BK1574","BK1515","BK1161"],"gpt_icon":0},{"id":"2603525776","title":"国家医保局，重拳出击！","url":"https://stock-news.laohu8.com/highlight/detail?id=2603525776","media":"中国基金报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603525776?lang=zh_cn&edition=full","pubTime":"2026-01-13 00:18","pubTimestamp":1768234680,"startTime":"0","endTime":"0","summary":"近期，国家医保局通报一起医药咨询服务企业涉商业贿赂案。对应时段内上述医生共开具万脉宁18275支。国家医保局于2020年建立价格招采信用评价制度，对法院判决、有关部门查处的医药购销行贿、带金销售等问题突出的企业开展失信评级，并采取限制挂网、配送等约束措施，使通过不当手段获取竞争优势的企业受到相应约束，使合规经营企业感受公平正义。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":null,"url":"http://mp.weixin.qq.com/s?__biz=MzA5MDEzNjQwMA==&mid=2656340430&idx=2&sn=307e9e121b1c199b7440586335e35f64&chksm=8a1d5528b0dc1502f1f7b649db6e5cb20222c076b3b49df72238a15df37d299ed612db0aca2a&scene=0#rd","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA5MDEzNjQwMA==&mid=2656340430&idx=2&sn=307e9e121b1c199b7440586335e35f64&chksm=8a1d5528b0dc1502f1f7b649db6e5cb20222c076b3b49df72238a15df37d299ed612db0aca2a&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09939","BK1515","BK1574"],"gpt_icon":0},{"id":"2603547735","title":"华昊中天医药-B01月12日获主力加仓16.5万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2603547735","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603547735?lang=zh_cn&edition=full","pubTime":"2026-01-12 16:15","pubTimestamp":1768205718,"startTime":"0","endTime":"0","summary":"01月12日，华昊中天医药-B股价收平报3.30元，成交金额27.2万元，换手率0.04%，振幅0.30%，量比1.69。华昊中天医药-B今日主力资金净流入16.5万元，上一交易日主力净流入17.5万元。该股近5个交易日下跌5.98%，主力资金累计净流入34.0万元；近20日主力资金累计净流入99.4万元，其中净流入天数为5日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112161810a710aaef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112161810a710aaef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1574","BK1161","02563","09939"],"gpt_icon":0},{"id":"2602591237","title":"1月12日三生国健跌6.25%，交银医药创新股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2602591237","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602591237?lang=zh_cn&edition=full","pubTime":"2026-01-12 15:38","pubTimestamp":1768203485,"startTime":"0","endTime":"0","summary":"证券之星消息，1月12日三生国健跌6.25%，收盘报59.81元，换手率1.51%，成交量9.32万手，成交额5.6亿元。重仓三生国健的前十大公募基金请见下表：该股最近90天内共有6家机构给出评级，买入评级4家，增持评级2家；过去90天内机构目标均价为75.26。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共19家，其中持有数量最多的公募基金为交银施罗德基金的交银医药创新股票A。该公募基金现任基金经理为楼慧源。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200015073.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","688336","09939","BK1161","BK1574","BK1515","BK0239"],"gpt_icon":0},{"id":"2602567685","title":"港股异动 | 阿里健康(00241)涨近4% 与北京梅尔森医药达成战略合作 贝美净®将于本周二全网首发","url":"https://stock-news.laohu8.com/highlight/detail?id=2602567685","media":"智通财经","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602567685?lang=zh_cn&edition=full","pubTime":"2026-01-12 11:25","pubTimestamp":1768188329,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，阿里健康涨近4%，截至发稿，涨3.29%，报5.96港元，成交额5.19亿港元。消息面上，据阿里健康官微消息，1月8日，阿里健康与北京梅尔森医药技术开发有限公司达成战略合作，共同宣布将在儿童专科创新药领域展开深度合作。贝美净不仅是全球首个针对该适应症的外用凝胶剂型，也标志着我国在儿童专用改良型新药研发领域取得了从科研创新到产业转化的重大突破。贝美净将于1月13日在阿里健康全网独家首发。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1391466.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1502","BK1615","BK1571","159938","BK1589","BK1584","BK1142","BK1610","BK1189","BK1515","BK1574","BK1617","09939","00241","BK1591","BK1161","BK1247","BK1501"],"gpt_icon":0},{"id":"2602960815","title":"“医药春晚”即将召开！","url":"https://stock-news.laohu8.com/highlight/detail?id=2602960815","media":"科创日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602960815?lang=zh_cn&edition=full","pubTime":"2026-01-12 10:15","pubTimestamp":1768184118,"startTime":"0","endTime":"0","summary":"文|张真当地时间1月12日，全球生物医药行业的“春晚”——第44届摩根大通全球医疗健康大会即将正式在美国召开，预计为期4天。截至目前，已有多家国内创新药企确认参会。除此之外，恒瑞医药、百利天恒、三生制药、荣昌生物等17家国产创新药企也将亮相亚太专场。上述机构进一步指出，BD常态化后，制药行业将回归产品全球价值验证。宜联生物将获得5.7亿美元首付款及近期里程碑付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112102905a70f9931&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112102905a70f9931&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09688","LU2488822045.USD","BK1515","09939","BK1588","BK1161"],"gpt_icon":0},{"id":"2602100513","title":"劲方医药-B盘中异动 早盘快速拉升5.01%报33.980港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2602100513","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602100513?lang=zh_cn&edition=full","pubTime":"2026-01-12 09:45","pubTimestamp":1768182304,"startTime":"0","endTime":"0","summary":"2026年01月12日早盘09时45分，劲方医药-B股票出现波动，股价大幅上涨5.01%。截至发稿，该股报33.980港元/股，成交量32.66万股，换手率0.10%，振幅5.75%。资金方面，该股资金流入406.205万港元，流出633.25万港元。劲方医药-B股票所在的药品行业中，整体涨幅为0.43%。其相关个股中，英硅智能、劲方医药-B、中国同辐涨幅较大，振幅较大的相关个股有先声药业、英硅智能、凯莱英，振幅分别为14.16%、7.34%、6.80%。该公司主要在中国国内和海外市场开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112094504a70f71a1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260112094504a70f71a1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1574","BK1161","02595","09939"],"gpt_icon":0},{"id":"2602559242","title":"医药生物行业跟踪周报：“十五五”聚焦脑机接口，抢占全球科技高地，建议关注：微创脑科学、翔宇医疗、美好医疗等【东吴医药朱国广团队】","url":"https://stock-news.laohu8.com/highlight/detail?id=2602559242","media":"国广有话说","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602559242?lang=zh_cn&edition=full","pubTime":"2026-01-11 21:24","pubTimestamp":1768137841,"startTime":"0","endTime":"0","summary":"海内外共振，加速抢占全球科技高地：脑机接口技术当前已经成为全球各国科技竞争的战略高地之一。当前全球脑机接口真处于爆发前夜，我国脑机接口产业有望迎来黄金发展期，建议关注微创脑科学、翔宇医疗、美好医疗等。从自免角度，建议关注康诺亚、益方生物、一品红等。从创新药龙头角度，建议关注百济神州、恒瑞医药等。从医疗器械角度，建议关注联影医疗、鱼跃医疗等。从中药角度，建议关注佐力药业、方盛制药、东阿阿胶等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260111213058a70ddf1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260111213058a70ddf1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02172","09939","09926","BK1100","03933","01276","09995","BK1617","BK1141","02615","BK1515","BK1574","02228","BK1161"],"gpt_icon":0},{"id":"2602853674","title":"每周股票复盘：*ST生物（000504）拟收购慧泽医药51%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2602853674","media":"证券之星","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602853674?lang=zh_cn&edition=full","pubTime":"2026-01-11 04:17","pubTimestamp":1768076227,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，*ST生物报收于8.84元，较上周的8.95元下跌1.23%。本周关注点公司公告汇总：*ST生物拟以现金收购湖南慧泽生物医药科技有限公司51%股权，交易构成重大资产重组。该事项已获董事会审议通过，不涉及关联交易，无需提交股东大会审议。亏损达净利润10%且超1000万元时需披露原因及套期有效性评估。南华生物拟以现金方式收购湖南慧泽生物医药科技有限公司51%股权，交易完成后慧泽医药将成为公司控股子公司并纳入合并报表范围。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100001430.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0086","159938","000504","BK0282","BK1515","BK1574","BK0042","09939","BK0046","BK1161"],"gpt_icon":0},{"id":"2602374424","title":"达仁堂：中新医药不再纳入合并报表范围","url":"https://stock-news.laohu8.com/highlight/detail?id=2602374424","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602374424?lang=zh_cn&edition=full","pubTime":"2026-01-09 22:12","pubTimestamp":1767967920,"startTime":"0","endTime":"0","summary":"证券日报网讯 1月9日，达仁堂在互动平台回答投资者提问时表示，2025年半年度及三季度购买商品、接受劳务支出的现金同比大幅下降，主要是2024年末公司将所属全资子公司天津中新医药有限公司（简称“中新医药”）的全部股权作价，增资津药太平医药有限公司，增资完成后，为公司的联营公司，中新医药不再纳入合并报表范围。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-09/doc-inhftpvi5683562.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-01-09/doc-inhftpvi5683562.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0164","BK0060","BK0239","09939","BK1161","600329","BK1574","BK1515","159938","BK0188","BK0028"],"gpt_icon":0},{"id":"2602062305","title":"一周医药速览（1.5-1.9）","url":"https://stock-news.laohu8.com/highlight/detail?id=2602062305","media":"财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602062305?lang=zh_cn&edition=full","pubTime":"2026-01-09 16:41","pubTimestamp":1767948068,"startTime":"0","endTime":"0","summary":"药明康德：实控人控制的股东累计减持2%公司股份近日，药明康德发布公告称，截至2026年1月5日，实际控制人控制的股东通过集中竞价和大宗交易方式累计减持公司股份5968万股，占公司总股本的2%。南华生物：筹划重大资产重组，拟以现金方式收购慧泽医药51%股权近日，南华生物发布公告称，其于2025年8月12日披露拟现金收购程泽能等合计持有的慧泽医药51%股权，交易完成后慧泽医药将成为其控股子公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109164318a7068476&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260109164318a7068476&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2045819591.USD","BK1141","BK1574","BK1583","LU2242644610.SGD","LU0320764599.SGD","09939","BK1576","LU0708995583.HKD","LU2125910500.SGD","BK1515","LU0052750758.USD","BK1161","02359","LU1046422090.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kintor.com.cn","stockEarnings":[{"period":"1week","weight":0.125},{"period":"1month","weight":0.1818},{"period":"3month","weight":0.0884},{"period":"6month","weight":-0.1269},{"period":"1year","weight":1.6},{"period":"ytd","weight":0.1939}],"compareEarnings":[{"period":"1week","weight":0.0052},{"period":"1month","weight":0.0336},{"period":"3month","weight":0.0362},{"period":"6month","weight":0.0959},{"period":"1year","weight":0.4225},{"period":"ytd","weight":0.0475}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"开拓药业有限公司是一家主要从事创新药产品研发的投资控股公司。该公司产品致力于解决未满足临床需求的疾病领域，管线主要涵盖皮科（如脱发、痤疮等）及肿瘤适应症。该公司在皮科领域有两款核心药物KX-826及GT20029。该公司在其他疾病领域包括转移性去势抗性前列腺癌（mCRPC）、肝癌、特发性肺纤维化、恶性血液疾病及多种实体瘤等。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.02053},{"month":2,"riseRate":0.8,"avgChangeRate":0.219909},{"month":3,"riseRate":0.4,"avgChangeRate":0.084454},{"month":4,"riseRate":0.6,"avgChangeRate":0.421119},{"month":5,"riseRate":0.6,"avgChangeRate":0.045244},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.066873},{"month":7,"riseRate":0.666667,"avgChangeRate":0.132768},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.071497},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.129033},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.103242},{"month":11,"riseRate":0.666667,"avgChangeRate":0.073526},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.185801}],"exchange":"SEHK","name":"开拓药业-B","nameEN":"KINTOR PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"开拓药业-B,09939,开拓药业-B股票,开拓药业-B股票老虎,开拓药业-B股票老虎国际,开拓药业-B行情,开拓药业-B股票行情,开拓药业-B股价,开拓药业-B股市,开拓药业-B股票价格,开拓药业-B股票交易,开拓药业-B股票购买,开拓药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"开拓药业-B(09939)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供开拓药业-B(09939)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}